Chandan Kumar Kedarisetty*, Sasanka Vangara and Varun Prabhakar

Department of Hepatology, Gleneagles Global Hospital, Lakdikapul, Hyderabad, India

*Corresponding Author: Chandan Kumar Kedarisetty, Department of Hepatology, Gleneagles Global Hospital, Lakdikapul, Hyderabad, India.

Received: June 05, 2023; Published: July 12, 2023

Abstract

End-stage liver cirrhosis is associated with progressive decompensation and manifestations of portal hypertension and complications of liver dysfunction. There is increasing evidence suggests that the intestinal microbial community plays important role in complications of cirrhosis. By modulating gut microbiota, it has expanded the horizon for newer therapeutic strategies for limiting these complications of portal hypertension. Encouraging data on use of probiotics in these patients has further exemplified the importance of identifying these unique gut microbiome signatures and develop personalized medicine for improved patient outcomes.

References

1. Schnabl B and Brenner DA. “Interactions between the intestinal microbiome and liver diseases”. Gastroenterology 146 (2014): 1513-1524.
2. Bajaj JS. “Alcohol, liver disease and the gut microbiota”. Nature Reviews Gastroenterology and Hepatology 16 (2019): 235-246.
3. Bajaj JS., et al. “Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation”. American Journal of Physiology-Gastrointestinal and Liver Physiology 303 (2012): 675-685.
4. Ciocan D., et al. “Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis”. Alimentary Pharmacology and Therapeutics 48 (2018): 961-974.
5. Vangara S., et al. “Comparative study of Gut Microbiome signatures in cirrhotics and their healthy donors undergoing living donor liver transplantation”. Journal of Clinical and Experimental HepatologyS2 (2022): S49-50.
6. Giannelli V., et al. “Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis”. World Journal of Gastroenterology45 (2014): 1679-1681.
7. Rashid SK., et al. “Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system”. PLoS One9 (2014): e97458.
8. Rincon D., et al. “Oral probiotic VSL#3 attenuates the circulatory disturbances in patients with cirrhosis and ascites”. Liver International10 (2014): 1504-1512.
9. Gupta N., et al. “Effects of the adjunctive probiotic VSL#3 on portal hemodynamics in patients with cirrhosis and large varices: a randomized trial”. Liver International8 (2013): 1148-1157.
10. Cyriac Abby Philips., et al. “Healthy Donor Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcoholic Hepatitis: A Pilot Study”. Clinical Gastroenterology and Hepatology4 (2017): 600-602.
11. Shen TC., et al. “Engineering the gut microbiota to treat hyperammonemia”. Journal of Clinical Investigation 125 (2015): 2841-2850.

Citation

Citation: Chandan Kumar Kedarisetty., et al. “Probiotics Role in Liver Diseases - A Magic Bullet?". Acta Scientific Gastrointestinal Disorders 6.8 (2023): 02-03.

Copyright

Copyright: © 2023 Chandan Kumar Kedarisetty., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.